Loading
The Uromigos

The Uromigos

The Uromigos

The Uromigos | August 22, 2022

John Kelly summarizes a recent paper published in JAMA that describes the benefits of robotic surgery versus open cystectomy.

The Uromigos

The Uromigos | August 15, 2022

Uromigos: Live and Unplugged, a first-ever, in-person event, will take place in Nashville from September 30 to October 1.

The Uromigos

The Uromigos | August 9, 2022

Bernard Escudier, MD, joins The Uromigos to talk about his career development and work in the field of kidney cancer.

The Uromigos

The Uromigos | August 1, 2022

Alex Wyatt joins The Uromigos to answer questions about ctDNA in prostate cancer and discuss his latest paper on that topic.

The Uromigos

The Uromigos | July 26, 2022

Declan Murphy and Matt Cooperberg debate the use of interventions in active surveillance for patients with prostate cancer.

The Uromigos

The Uromigos | July 18, 2022

Dr. Oliver Sartor, medical director of Tulane Cancer Center, discusses his career development and work in prostate cancer.

The Uromigos

The Uromigos | July 11, 2022

Kimryn Rathmell, MD, PhD, discusses highlights from the kidney cancer guidelines presented at the ASCO Annual Meeting.

The Uromigos

The Uromigos | June 27, 2022

Darren Feldman describes different approaches to relapsed germ cell tumors and the TIGER study.

The Uromigos

The Uromigos | June 20, 2022

Neal Shore describes his recent controversial paper and the over-treatment of patients with low-grade disease.

The Uromigos

The Uromigos | June 20, 2022

Phillip Kuo discusses phase 3 of the VISION trial that utilizes Lutetium-177 for the treatment of prostate cancer.

The Uromigos

The Uromigos | June 7, 2022

Veda Giri discusses germline variants among African American males and specific genes related to prostate cancer.

The Uromigos

The Uromigos | June 5, 2022

Data from the ENZAMET trial reconfirms survival benefit with enzalutamide in mHSPC, but the role of docetaxel is uncertain.

The Uromigos

The Uromigos | June 5, 2022

Matt Galsky discusses research posters presented that cover the effects of HER2-targeting ADCs for urothelial cancer.

The Uromigos

The Uromigos | June 4, 2022

Nazli Dizman covers an update on the CBM588 probiotic strain and its phase II trial.

The Uromigos

The Uromigos | June 4, 2022

Amir Goldkorn, MD, discusses findings from a phase 2 bladder trial, responses to neoadjuvant chemotherapy, and more.

The Uromigos

The Uromigos | June 3, 2022

Robert Jones, MD, talks about the hypothesis for ATLANTIS, its specific trial results, and more.

The Uromigos

The Uromigos | June 3, 2022

Christopher W. Ryan, MD, shares long-awaited data about adjuvant everolimus in kidney cancer, the EVEREST trial, and results.

The Uromigos

The Uromigos | May 23, 2022

Jonathan Rosenberg gives an overview of the current landscape of antibody drug conjugates and their adverse effects.

The Uromigos

The Uromigos | May 16, 2022

Silke Gillessen and Chris Sweeney summarize the 2022 APCCC meeting.

The Uromigos

The Uromigos | May 9, 2022

Syed Hussein and Sam Funt describe their studies on this topic.